US 12,290,505 B2
Tissue factor-targeted antibody-drug conjugate
Ke Yu, Shanghai (CN); Jingkang Shen, Shanghai (CN); Tao Meng, Shanghai (CN); Lanping Ma, Shanghai (CN); Xuesai Zhang, Shanghai (CN); Qingrou Li, Shanghai (CN); and Qing Lin, Shanghai (CN)
Assigned to FUDAN UNIVERSITY, Shanghai (CN); SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai (CN); and SHANGHAI MIRACOGEN INC., Shanghai (CN)
Filed by FUDAN UNIVERSITY, Shanghai (CN); SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai (CN); and SHANGHAI MIRACOGEN INC., Shanghai (CN)
Filed on Oct. 27, 2022, as Appl. No. 18/050,240.
Application 18/050,240 is a continuation of application No. 16/326,886, granted, now 11,534,495, previously published as PCT/CN2017/087779, filed on Jun. 9, 2017.
Claims priority of application No. 201610704559.1 (CN), filed on Aug. 22, 2016; and application No. 201710125244.6 (CN), filed on Mar. 3, 2017.
Prior Publication US 2023/0138930 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 31/40 (2006.01); A61K 31/4025 (2006.01); A61K 31/5365 (2006.01); A61K 31/537 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/36 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 31/4025 (2013.01); A61K 31/5365 (2013.01); A61K 31/537 (2013.01); A61K 47/542 (2017.08); A61K 47/545 (2017.08); A61K 47/68 (2017.08); A61K 47/68031 (2023.08); A61K 47/68033 (2023.08); A61K 47/6843 (2017.08); A61P 35/00 (2018.01); C07K 16/36 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/90 (2013.01)] 13 Claims
 
1. A method for treating a tissue factor (TF)-related disease, comprising administering a therapeutically effective amount of the antibody-drug conjugate or a pharmaceutical composition comprising the antibody-drug conjugate to a subject in need thereof,
wherein the antibody-drug conjugate comprises:
(a) an antibody moiety, wherein the heavy chain variable region of the antibody comprises the following three complementary determining regions (CDRs):
(H1) CDR1 as set forth in SEQ ID NO: 1,
(H2) CDR2 as set forth in SEQ ID NO: 2, and
(H3) CDR3 as set forth in SEQ ID NO: 3, and
the light chain variable region of the antibody comprises the following three complementary determining regions (CDRs):
(L1) CDR1′ as set forth in SEQ ID NO: 4,
(L2) CDR2′ as set forth in SEQ ID NO: 5, and
(L3) CDR3′ as set forth in SEQ ID NO: 6, and
(b) a conjugation moiety conjugated to the antibody moiety, wherein the conjugation moiety is Monomethyl auristatin E (MMAE); and
wherein the TF-related disease is tumorigenesis, tumor growth, or tumor metastasis, the tumor is a tumor with high TF expression, and the tumor is pancreatic cancer, triple negative breast cancer, cervical cancer, lung cancer or malignant glioma.